Table 5.
ALT Elevation Eventsa by Severity in GTE and Placebo Groups
Total Events (No.) | # Participants (%) with Adverse Eventsb |
||||||
---|---|---|---|---|---|---|---|
|
|||||||
GTE | Placebo | Total | GTE (n=538) |
Placebo (n=537) |
P-value | ||
|
|||||||
53 | 4 | 57 | 36 (6.7) | 4 (0.7) | <0.001 | ||
| |||||||
Grade (Severity)c | 1 | 39 | 4 | 43 | 22 (4.1) | 4 (0.7) | <0.001 |
2 | 7 | 0 | 7 | 7 (1.3) | 0 (0) | 0.02d | |
3 | 6 | 0 | 6 | 6 (1.1) | 0 (0) | 0.03d | |
4 | 1 | 0 | 1 | 1 (0.2) | 0 (0) | 1.00d |
ALT elevation listed in “Investigations’ system category in Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
Data presented as number of participants (% total participants). For participants who reported multiple ALT elevations, the most severe elevation per subject is presented.
Grade: 1=mild; 2=moderate; 3=severe; 4=life-threatening.
Based on Fisher’s exact test.
Abbreviation: GTE, green tea extract.